(681 days)
Not Found
No
The document describes an "algorithm" for determining MIC and SIR, but there is no mention of AI, ML, or any related techniques like neural networks, deep learning, or image processing which are commonly associated with AI/ML in this context. The description focuses on metabolic assays and comparing growth data to determine MIC, which aligns with traditional automated susceptibility testing methods.
No.
This device is an in vitro diagnostic (IVD) device used for identifying the susceptibility of microorganisms to antimicrobial agents, rather than directly treating a disease or condition.
Yes
Explanation: The Selux AST System is intended for "automated quantitative susceptibility testing," which means it determines the susceptibility of microorganisms to antimicrobial agents. This information is crucial for clinicians to diagnose and treat infections effectively. The "Indications for Use" explicitly states it's an "in vitro test to determine the susceptibility," directly indicating its role in diagnostics.
No
The device description explicitly states that the Selux AST System consists of hardware components including a Sample Prep Station, an Inoculator, an Analyzer, and a computer workstation, in addition to the software.
Based on the provided text, the Selux AST System is indeed an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The Intended Use explicitly states it's for "automated quantitative susceptibility testing for most clinically significant aerobic microorganisms." This is a diagnostic test performed outside of the body (in vitro) on biological samples (microorganisms).
- Indications for Use: The Indications for Use further clarifies that the Selux Gram-Negative Panel is intended for use "as an in vitro test to determine the susceptibility of isolated colonies of specific gram-negative bacilli to specific antimicrobial agents." The phrase "in vitro test" directly indicates it's an IVD.
- Device Description: The description details a system that analyzes microbial growth in wells containing antimicrobial agents to determine susceptibility. This process is performed in a laboratory setting on a biological sample.
- Principle of Operation: The principle of operation describes a method similar to broth microdilution, a standard in vitro diagnostic technique for determining antimicrobial susceptibility.
- Clinical Performance Testing: The description of clinical performance testing involves evaluating the system's performance against a reference method using clinical isolates, which is typical for validating an IVD.
Therefore, the Selux AST System fits the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Selux AST System is intended to be used for the automated quantitative susceptibility testing for most clinically significant aerobic microorganisms. The Selux AST System does not provide organism identification.
The Selux Gram-Negative Panel is intended for use with the Selux AST System as an in vitro test to determine the susceptibility of isolated colonies of specific gram-negative bacilli to specific antimicrobial agents when used as instructed.
The Selux Gram-Negative Panel is a quantitative test for the following antimicrobial agents with the specific organisms identified below:
- Amikacin: Pseudomonas aeruginosa
- Amoxicillin-Clavulanate: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Proteus mirabilis
- Ampicillin: Escherichia coli, Proteus mirabilis
- Ampicillin-Sulbactam: Acinetobacter baumannii complex, Escherichia species (including K. oxytoca, K. pneumoniae), Proteus mirabilis, Proteus vulgaris
- Aztreonam: Escherichia coli
- Cefazolin: Escherichia coli, Klebsiella pneumoniae
- Cefepime: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, . Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- Cefoxitin: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Morganii
- Ceftazidime: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. pneumoniae), Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- Ceftazidime-Avibactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens
- Ceftriaxone: Citrobacter freundii complex, Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis
- . Ciprofloxacin: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa
- Eravacycline: Citrobacter freundii complex, Enterobacter cloacae complex, Escherichia oxytoca
- Ertapenem: Citrobacter freundii complex, Citrobacter koseri, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- Gentamicin: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae), Proteus species (including P. mirabilis, P. vulgaris), Pseudomonas aeruginosa, Serratia marcescens
- Imipenem-Relebactam: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Pseudomonas aeruginosa
- Levofloxacin: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- . Meropenem: Citrohacter freundii complex. Citrobacter cloacae complex. Escherichia coli. Klebsiella oxvtoca, Klebsiella pneumoniae, Morganella morganii. Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens
- Meropenem-Vaborbactam: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Morganella morganii, Serratia marcescens
- Minocycline: Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)
- Piperacillin-Tazobactam: Citrobacter koseri, Escherichia coli, Klebsiella pneumoniae, Morganii, Proteus mirabilis, Proteus vulgaris
- Tobramycin: Pseudomonas aeruginosa .
- Trimethoprim-Sulfamethoxazole: Enterobacter cloacae complex, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)
Product codes
LON, LTT, LTW
Device Description
The Selux AST System for antimicrobial susceptibility testing (AST) consists of a Sample Prep Station, an Inoculator, an Analyzer, a computer workstation, and the reagents and consumables required to perform AST testing. The system is operated via software that guides users through the manual sample preparation process and operates the automated Inoculator and Analyzer. The software includes an algorithm that enables the system to determine the susceptibilities of an organism to the variety of antimicrobials under test.
The system is designed so that only Gram stain information is required to initiate testing (to select the proper antimicrobial panel, gram-negative or gram-positive). While complete system testing can be performed without species-level identification (ID), this information is required for the system to report susceptibility results. Species ID can be performed by any appropriate method and this information can be either manually input to the Selux system or automatically downloaded from the laboratory information system (LIS) at any time, once the sample ID is entered into the । ।। :: :
The system utilizes 384-well panels to provide parallel results for a large number of antimicrobials. Its average time-to-result is under 6 hours, as demonstrated in various studies.
Principle of Operation
The Selux platform performs AST similarly to the reference broth microdilution method by first incubating samples, then quantifying microbial growth in each well of an antimicrobial dilution series after a growth period, and finally determining the MIC by comparing growth data in each well. The Selux AST test requires that the Gram type (Classification) of the organism be known prior to testing as the information is necessary to select the proper AST panel to use. The organism identification (ID) need not be known for Selux AST processing to be performed. However, the organism ID is necessary for a result to be obtained because the MIC-determining algorithm is species-specific as is the interpretative Susceptible, Intermediate, or Resistant (SIR) determination. Any FDA-cleared method may be used to provide an ID including biochemical techniques, matrixassisted laser desorption/isotherm mass spectrometry, and multiplex genetic assays.
To ensure accurate results, the Selux method initiates antimicrobial susceptibility assays only after sufficient microorganism replication has occurred. Following determination of sufficient growth, two complementary metabolic assays are performed that quantify microbial growth, namely an indicator assay to estimate the number of bacteria present and a surface binding assay. These data are input to an MIC-determining algorithm that provides results when organism IDs are available. The sufficient growth assay ensures that the metabolic reagents used for the high-sensitivity organism quantification assays are not added until after sufficient microbial growth has occurred. To get an accurate reading of microbial replication, the sufficient growth assay monitors growth in dedicated AST panel wells that contain organisms and cation-adjusted Mueller-Hinton Broth but no antimicrobials or probes. Sufficient growth assay wells are monitored by fluorescence to those wells which the standard viability assay pair resazurin/methylene blue have been added and/or by optical absorbance.
Two probe-based assays, a viability assay and a surface area assay, commence across all wells in the panel after the sufficient growth threshold has been met. Both of these assays are performed in each AST panel well, providing two complementary datasets for each well.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Clinical performance testing on the Selux AST System was performed at three test sites. Contemporary and frozen clinical isolates from diverse geographic locations across the US were evaluated for performance as were banked challenge isolates, which were selected for their resistance profiles. A total of 1401 clinical (426 contemporary and 975 stock) and 222 challenge isolates from 12 Enterobacterales species, Acinetobacter baumannii complex, and Pseudomonas aeruginosa were tested to evaluate the Selux AST System performance for 24 antimicrobials. Depending on the spectrum of activity, breakpoints, and the claimed organisms (species/group) for each antimicrobial on the panel, the number of datapoints for the various antimicrobialorganisms tested varied and ranged from 165 (e.g. P. aeruginosa/Imipenem-Relebactam) to 977 (e.g. Enterobacterales/Ertapenem).
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Reproducibility Study:
- Inter-site reproducibility: Evaluated by testing a minimum of 25 isolates for each of the 24 antimicrobials at each of three test sites that participated in the clinical study. Each isolate was tested once at each site for a total of three results per isolate (minimum of 75 results per antimicrobial).
- Best-case inter-site reproducibility was ≥95%.
- Worst-case inter-site reproducibility was ≥89%.
- Intra-site reproducibility: Evaluated at a single site that participated in the inter-site reproducibility testing and the clinical study. A minimum of 5 isolates for each antimicrobial were tested in triplicate at the site from three separate inoculums on three separate days for a minimum total of 45 results per antimicrobial.
- Best-case intra-site reproducibility was ≥95%.
- Worst-case intra-site reproducibility was ≥89%.
Clinical Studies:
- Study Type: Clinical performance testing comparing Selux AST System results with triplicate broth microdilution results performed at an independent reference laboratory.
- Sample Size: A total of 1401 clinical (426 contemporary and 975 stock) and 222 challenge isolates from 12 Enterobacterales species, Acinetobacter baumannii complex, and Pseudomonas aeruginosa were tested for 24 antimicrobials. The number of datapoints for various antimicrobial-organisms ranged from 165 to 977.
- Key Results: The Selux AST System meets performance criteria for each indication. QC testing met the 95% performance criteria for all antimicrobials.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
The document presents categorical agreement (CA), essential agreement (EA), and error rates (VMJ, MAJ, MIN) for each antimicrobial-organism combination rather than sensitivity, specificity, PPV, or NPV.
Essential Agreement (EA) and Categorical Agreement (CA) for Clinical Performance:
- Amikacin/Pseudomonas aeruginosa: EA: 90.9%, CA: 98.2%
- Amoxicillin-Clavulanate/Enterobacterales: EA: 95.6%, CA: 92.6%
- Ampicillin/Enterobacterales: EA: 94.9%, CA: 98.8%
- Ampicillin-Sulbactam/Acinetobacter baumannii complex: EA: 91.9%, CA: 92.7%
- Aztreonam/Enterobacterales: EA: 97.8%, CA: 97.3%
- Cefazolin/Enterobacterales: EA: 94.7%, CA: 80.2%
- Cefepime/Enterobacterales: EA: 94.4%, CA: 95.8%
- Cefoxitin/Enterobacterales: EA: 92.3%, CA: 79.1%
- Ceftazidime/Enterobacterales: EA: 95.6%, CA: 96.4%
- Ceftazidime-Avibactam/Enterobacterales: EA: 97.3%, CA: 99.4%
- Ceftazidime-Avibactam/Pseudomonas aeruginosa: EA: 92.6%, CA: 96.9%
- Ceftriaxone/Enterobacterales: EA: 97.3%, CA: 98.4%
- Ciprofloxacin/Enterobacterales: EA: 96.7%, CA: 96.2%
- Ciprofloxacin/Pseudomonas aeruginosa: EA: 95.9%, CA: 94.7%
- Eravacycline/Enterobacterales: EA: 98.2%, CA: 98.6%
- Ertapenem/Enterobacterales: EA: 96.3%, CA: 98.4%
- Gentamicin/Enterobacterales: EA: 96.2%, CA: 98.9%
- Gentamicin/Pseudomonas aeruginosa: EA: 96.8%, CA: 97.2%
- Imipenem-Relebactam/Enterobacterales: EA: 93.4%, CA: 97.5%
- Imipenem-Relebactam/Pseudomonas aeruginosa: EA: 96.4%, CA: 98.2%
- Levofloxacin/Enterobacterales: EA: 96%, CA: 94.9%
- Meropenem/Enterobacterales: EA: 96.2%, CA: 98%
- Meropenem/Pseudomonas aeruginosa: EA: 93.1%, CA: 96%
- Meropenem-Vaborbactam/Enterobacterales: EA: 95.7%, CA: 98.9%
- Minocycline/Enterobacterales: EA: 90.3%, CA: 95.1%
- Piperacillin-Tazobactam/Enterobacterales: EA: 92.1%, CA: 97.3%
- Tobramycin/Pseudomonas aeruginosa: EA: 93.4%, CA: 97.6%
- Trimethoprim-Sulfamethoxazole/Enterobacterales: EA: 96.9%, CA: 98.4%
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
April 19, 2023
Selux Diagnostics, Inc % Patricia Shrader Regulatory Consultant PBO Consulting 2212 East Pratt Street Baltimore, Maryland 21231
Re: K211748
Trade/Device Name: Selux AST System; Model AST Gen 1.0 Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System Regulatory Class: Class II Product Code: LON, LTT, LTW Dated: June 4, 2021 Received: June 7, 2021
Dear Patricia Shrader:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Ribhi Shawar -S
Ribhi Shawar, Ph.D. (ABMM) Branch Chief. General Bacteriology and Antimicrobial Susceptibility Branch Division of Microbiology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K211748
Device Name Selux AST System
Indications for Use (Describe)
Intended Use:
The Selux AST System is intended to be used for the automated quantitative susceptibility testing for most clinically significant aerobic microorganisms. The Selux AST System does not provide organism identification.
Indications for Use:
The Selux Gram-Negative Panel is intended for use with the Selux AST System as an in vitro test to determine the susceptibility of isolated colonies of specific gram-negative bacilli to specific antimicrobial agents when used as instructed.
The Selux Gram-Negative Panel is a quantitative test for the following antimicrobial agents with the specific organisms identified below:
- Amikacin: Pseudomonas aeruginosa
- Amoxicillin-Clavulanate: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Proteus ● mirabilis
- Ampicillin: Escherichia coli, Proteus mirabilis ●
- Ampicillin-Sulbactam: Acinetobacter baumannii complex, Escherichia species (including K. oxytoca, ● K. pneumoniae), Proteus mirabilis, Proteus vulgaris
- Aztreonam: Escherichia coli ●
- Cefazolin: Escherichia coli, Klebsiella pneumoniae ●
- Cefepime: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, . Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- Cefoxitin: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Morganii
- Ceftazidime: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter cloacae complex, ● Escherichia coli, Klebsiella species (including K. aerogenes, K. pneumoniae), Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- Ceftazidime-Avibactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, ● Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens
- Ceftriaxone: Citrobacter freundii complex, Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis
- . Ciprofloxacin: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa
- Eravacycline: Citrobacter freundii complex, Enterobacter cloacae complex, Escherichia oxytoca ●
- Ertapenem: Citrobacter freundii complex, Citrobacter koseri, Klebsiella oxytoca, Klebsiella ● pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- Gentamicin: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae), Proteus species (including P. mirabilis, P. vulgaris), Pseudomonas aeruginosa, Serratia marcescens
- Imipenem-Relebactam: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Pseudomonas aeruginosa
3
- Levofloxacin: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- . Meropenem: Citrohacter freundii complex. Citrobacter cloacae complex. Escherichia coli. Klebsiella oxvtoca, Klebsiella pneumoniae, Morganella morganii. Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens
- Meropenem-Vaborbactam: Citrobacter freundii complex, Citrobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Morganella morganii, Serratia marcescens
- Minocycline: Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)
- Piperacillin-Tazobactam: Citrobacter koseri, Escherichia coli, Klebsiella pneumoniae, Morganii, ● Proteus mirabilis, Proteus vulgaris
- Tobramycin: Pseudomonas aeruginosa .
- Trimethoprim-Sulfamethoxazole: Enterobacter cloacae complex, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
5
510(k) Summary for the Selux AST System, Antimicrobial Susceptibility Test System
Date prepared: April 9, 2023
Submitter:
Selux Diagnostics, Inc. 56 Roland St Suite 106 Charlestown, MA 02129 Tel. 617-945-9383
Contact:
Eric Stern, Ph.D. Tel. 617-945-9383
Subject Device
| Trade Name: | Selux AST System |
|---|---|
| Common Name: | Antimicrobial Susceptibility Test System |
| Regulation Number: | 21 CFR 866.1645 |
| Regulation Name: | Fully automated short-term incubation cycle antimicrobial susceptibility |
| system | |
| Regulatory Class: | Class II |
| Product Code: | LON, LTT, LTW |
| Classification Panel: | 83 (Microbiology) |
Primary Predicate Device(s)
| Trade Name: | BD Phoenix Automated Microbiology System- Ceftaroline 0.0156-4
µg/mL |
|-----------------------|------------------------------------------------------------------------------------|
| Manufacturer: | Becton, Dickinson and Company |
| 510(k) Reference: | K190905 |
| Common Name: | Antimicrobial Susceptibility Test System |
| Regulation Number: | 21 CFR 866.1645 |
| Regulation Name: | Fully automated short-term incubation cycle antimicrobial susceptibility
system |
| Regulatory Class: | Class II |
| Product Code: | LON |
| Classification Panel: | 83 (Microbiology) |
Device Description
The Selux AST System for antimicrobial susceptibility testing (AST) consists of a Sample Prep Station, an Inoculator, an Analyzer, a computer workstation, and the reagents and consumables required to perform AST testing. The system is operated via software that guides users through the manual sample preparation process and operates the automated Inoculator and Analyzer. The software includes an algorithm that enables the system to determine the susceptibilities of an organism to the variety of antimicrobials under test.
6
The system is designed so that only Gram stain information is required to initiate testing (to select the proper antimicrobial panel, gram-negative or gram-positive). While complete system testing can be performed without species-level identification (ID), this information is required for the system to report susceptibility results. Species ID can be performed by any appropriate method and this information can be either manually input to the Selux system or automatically downloaded from the laboratory information system (LIS) at any time, once the sample ID is entered into the । ।। :: :
The system utilizes 384-well panels to provide parallel results for a large number of antimicrobials. Its average time-to-result is under 6 hours, as demonstrated in various studies.
Principle of Operation
The Selux platform performs AST similarly to the reference broth microdilution method by first incubating samples, then quantifying microbial growth in each well of an antimicrobial dilution series after a growth period, and finally determining the MIC by comparing growth data in each well. The Selux AST test requires that the Gram type (Classification) of the organism be known prior to testing as the information is necessary to select the proper AST panel to use. The organism identification (ID) need not be known for Selux AST processing to be performed. However, the organism ID is necessary for a result to be obtained because the MIC-determining algorithm is species-specific as is the interpretative Susceptible, Intermediate, or Resistant (SIR) determination. Any FDA-cleared method may be used to provide an ID including biochemical techniques, matrixassisted laser desorption/isotherm mass spectrometry, and multiplex genetic assays.
To ensure accurate results, the Selux method initiates antimicrobial susceptibility assays only after sufficient microorganism replication has occurred. Following determination of sufficient growth, two complementary metabolic assays are performed that quantify microbial growth, namely an indicator assay to estimate the number of bacteria present and a surface binding assay. These data are input to an MIC-determining algorithm that provides results when organism IDs are available. The sufficient growth assay ensures that the metabolic reagents used for the high-sensitivity organism quantification assays are not added until after sufficient microbial growth has occurred. To get an accurate reading of microbial replication, the sufficient growth assay monitors growth in dedicated AST panel wells that contain organisms and cation-adjusted Mueller-Hinton Broth but no antimicrobials or probes. Sufficient growth assay wells are monitored by fluorescence to those wells which the standard viability assay pair resazurin/methylene blue have been added and/or by optical absorbance.
Two probe-based assays, a viability assay and a surface area assay, commence across all wells in the panel after the sufficient growth threshold has been met. Both of these assays are performed in each AST panel well, providing two complementary datasets for each well.
7
Intended Use and Indications for Use
The Selux AST System is intended to be used for the automated quantitative or qualitative susceptibility testing for most clinically significant aerobic microorganisms. The Selux AST System does not provide organism identification.
The Selux Gram-Negative Panel is intended for use with the Selux AST System as an in-vitro test to determine the susceptibility of isolated colonies of specific gram-negative bacilli to specific antimicrobial agents when used as instructed.
The Selux Gram-Negative Panel is a quantitative test for the following antimicrobial agents with the specific organisms identified below:
- . Amikacin: Pseudomonas aeruginosa
- . Amoxicillin-Clavulanate: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae). Proteus mirabilis
- Ampicillin: Escherichia coli, Proteus mirabilis
- . Ampicillin-Sulbactam: Acinetobacter baumannii complex, Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Proteus mirabilis, Proteus vulgaris
- Aztreonam: Escherichia coli
- Cefazolin: Escherichia coli, Klebsiella pneumoniae
- Cefepime: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae . complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- . Cefoxitin: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Morganella morganii
- . Ceftazidime: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxvtoca, K. pneumoniae), Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- . Ceftazidime-Avibactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens
- . Ceftriaxone: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis
- Ciprofloxacin: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa
- . Eravacycline: Citrobacter freundii complex, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca
- . Ertapenem: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
8
- Gentamicin: Citrobacter species (including C. freundii complex, C. koserì), . Enterobacter cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae), Proteus species (including P. mirabilis, P. vulgaris), Pseudomonas aeruginosa, Serratia marcescens
- . Imipenem-Relebactam: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Pseudomonas aeruginosa
- . Levofloxacin: Citrobacter freundii complex. Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
- . Meropenem: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens
- . Meropenem-Vaborbactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxvtoca. Klebsiella pneumoniae, Morganella morganii, Serratia marcescens
- . Minocycline: Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)
- . Piperacillin-Tazobactam: Citrobacter koseri, Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris
- . Tobramycin: Pseudomonas aeruginosa
- . Trimethoprim-Sulfamethoxazole: Enterobacter cloacae complex, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)
Comparison of Technological Characteristics with the Predicate Device
The technological characteristics of the Selux AST System are substantially equivalent to the predicate, the BD Phoenix Automated Microbiology System- Ceftaroline 0.0156-4 ug/mL (K190905) in terms of intended use, application, user population, basic design, performance, and labeling.
| Specification | Selux AST System | K190905 |
|---|---|---|
| Device Trade Name | Selux AST System | BD Phoenix Automated |
| Microbiology System- | ||
| Ceftaroline 0.0156-4 µg/mL | ||
| Indication for Use | The Selux AST System is intended to be | |
| used for the automated quantitative or | ||
| qualitative susceptibility testing for most | ||
| clinically significant aerobic | ||
| microorganisms. The Selux AST System | ||
| does not provide organism identification. |
The Selux Gram-Negative Panel is
intended for use with the Selux AST
System as an in vitro test to determine the
susceptibility of isolated colonies of
specific gram-negative bacilli to specific | The BD Phoenix Automated
Microbiology System is intended
for the in vitro rapid identification
(ID) of aerobic and facultative
anaerobic Gram-negative
bacteria. The BD Phoenix
Automated Microbiology System is
also intended for the quantitative
determination of antimicrobial
susceptibility by minimal inhibitory
concentration (MIC) of aerobic and
facultative anaerobic Gram- |
| Specification | Selux AST System | K190905 |
| | antimicrobial agents when used as
instructed. | negative bacteria isolates from pure
culture. |
| Sources of
Microorganisms | Bacterial colonies isolated from culture | Same |
| Technology | Automated growth-based detection | Same |
| Methodology | Determinations of MIC using serial two-
fold dilution format | Same |
| Read Method | Automated | Same |
| Inoculation Method | Automated | Same |
| Result Reported | Report results as minimum inhibitory
concentration (MIC) and categorical
interpretation (S, I, R, NS) | Report results as minimum
inhibitory concentration (MIC) and
categorical interpretation (S, I, R) |
| General Device Characteristic Differences | | |
| Antimicrobial Agent and
Reporting Range | Amikacin: ≤2 to ≥256 µg/mL
Amoxicillin-Clavulanate: ≤0.5 to ≥128
µg/mL
Ampicillin: ≤0.25 to ≥128 µg/mL
Ampicillin-Sulbactam: ≤0.5 to ≥128
µg/mL
Aztreonam: ≤0.03 to ≥128 µg/mL
Cefazolin: ≤0.12 to ≥128 µg/mL
Cefepime: ≤0.25 to ≥128 µg/mL
Cefoxitin: ≤1 to ≥128 µg/mL
Ceftazidime: ≤2 to ≥64 µg/mL
Ceftazidime-Avibactam: ≤0.12 to ≥64
µg/mL
Ceftriaxone: ≤0.25 to ≥32 µg/mL
Ciprofloxacin: ≤0.03 to ≥16 µg/mL
Eravacycline: ≤0.016 to ≥4 µg/mL
Ertapenem: ≤0.03 to ≥16 µg/mL
Gentamicin: ≤0.06 to ≥64 µg/mL
Imipenem-Relebactam: ≤0.03 to ≥128
µg/mL
Levofloxacin: ≤0.06 to ≥32 µg/mL
Meropenem: ≤0.5 to ≥64 µg/mL
Meropenem-Vaborbactam: ≤0.06 to
≥64 µg/mL
Minocycline: ≤1 to ≥64 µg/mL
Piperacillin-Tazobactam: ≤4 to ≥512
µg/mL
Tobramycin: ≤0.12 to ≥128 µg/mL
Trimethoprim-Sulfamethoxazole:
≤0.12 to ≥32 µg/mL | Ceftaroline: ≤0.0156 to ≥8 µg/mL |
| IVD Functions | AST | ID and AST |
| Instrument | Selux AST System | BD Phoenix Automated
Microbiology System |
9
10
Despite the differences between the Selux AST System and the predicate, the overall risk and safety of system use is not affected.
Reproducibility
Inter-site reproducibility was evaluated by testing a minimum of 25 isolates for each of the 24 antimicrobials at each of three test sites that participated in the clinical study. Each isolate was tested once at each site for a total of three results per isolate (minimum of 75 results per antimicrobial). Best-case inter-site reproducibility was ≥95% and worst-case inter-site reproducibility was ≥89% (see following table).
| Selux AST System Inter-site Reproducibility | ||||
|---|---|---|---|---|
| All organisms (combined) | Indicated organisms only | |||
| Antimicrobial | Best-case (%) | Worst case (%) | Best-case (%) | Worst case (%) |
| Amikacin | 98/104 (94.2%) | 98/104 (94.2%) | 92/98 (93.9%) | 92/98 (93.9%) |
| Amoxicillin-Clavulanate | 71/72 (98.6%) | 70/72 (97.2%) | 71/72 (98.6%) | 70/72 (97.2%) |
| Ampicillin | 72/75 (96.0%) | 72/75 (96.0%) | 68/69 (98.6%) | 68/69 (98.6%) |
| Ampicillin-Sulbactam | 74/75 (98.7%) | 74/75 (98.7%) | 66/66 (100%) | 66/66 (100%) |
| Aztreonam | 77/78 (98.7%) | 75/78 (96.2%) | 77/78 (98.7%) | 75/78 (96.2%) |
| Cefazolin | 77/81 (95.1%) | 76/81 (93.8%) | 68/72 (94.4%) | 67/72 (93.1%) |
| Cefepime | 77/78 (98.7%) | 76/78 (97.4%) | 77/78 (98.7%) | 76/78 (97.4%) |
| Cefoxitin | 70/72 (97.2%) | 69/72 (95.8%) | 70/72 (97.2%) | 69/72 (95.8%) |
| Ceftazidime1 | 77/81 (95.1%) | 71/81 (87.7%) | 77/81 (95.1%) | 71/81 (87.7%) |
| Ceftazidime-Avibactam | 140/144 (97.2%) | 139/144 (96.5%) | 140/144 (97.2%) | 139/144 (96.5%) |
| Ceftriaxone | 140/141 (99.3%) | 140/141 (99.3%) | 140/141 (99.3%) | 140/141 (99.3%) |
| Ciprofloxacin | 74/75 (98.7%) | 71/75 (94.7%) | 74/75 (98.7%) | 71/75 (94.7%) |
| Eravacycline | 78/78 (100%) | 78/78 (100%) | 78/78 (100%) | 78/78 (100%) |
| Ertapenem | 143/145 (98.6%) | 143/145 (98.6%) | 143/145 (98.6%) | 143/145 (98.6%) |
| Gentamicin | 77/80 (96.3%) | 77/80 (96.3%) | 77/80 (96.3%) | 77/80 (96.3%) |
| Imipenem | 145/149 (97.3%) | 140/149 (94.0%) | 145/149 (97.3%) | 140/149 (94.0%) |
| Imipenem-Relebactam | 72/75 (96.0%) | 72/75 (96.0%) | 72/75 (96.0%) | 72/75 (96.0%) |
| Levofloxacin | 76/78 (97.4%) | 76/78 (97.4%) | 76/78 (97.4%) | 76/78 (97.4%) |
| Meropenem | 75/78 (96.2%) | 73/78 (93.6%) | 70/72 (97.2%) | 68/72 (94.4%) |
| Meropenem-Vaborbactam | 142/145 (97.9%) | 132/145 (91.0%) | 133/143 (93.0%) | 133/143 (93.0%) |
| Minocycline | 73/75 (97.3%) | 73/75 (97.3%) | 64/66 (97.3%) | 64/66 (97.3%) |
| Piperacillin-Tazobactam | 72/75 (96.0%) | 69/75 (92.0%) | 63/66 (95.5%) | 60/66 (90.9%) |
| Tobramycin | 74/78 (94.9%) | 73/78 (93.6%) | 74/78 (94.9%) | 73/78 (93.6%) |
| Trimethoprim-Sulfamethoxazole | 143/148 (96.6%) | 142/148 (95.9%) | 143/148 (96.6%) | 142/148 (95.9%) |
Intra-site reproducibility was evaluated at a single site that participated in the inter-site reproducibility testing and the clinical study. A minimum of 5 isolates for each antimicrobial were tested in triplicate at the site from three separate inoculums on three separate days for a minimum total of 45 results per antimicrobial. Best-case intra-site reproducibility was ≥95% and worst-case intra-site reproducibility was ≥89% (see following table).
11
| Selux AST System Intra-site Reproducibility | ||||
|---|---|---|---|---|
| All organisms (combined) | Indicated organisms only | |||
| Antimicrobial | Best-case (%) | Worst case (%) | Best-case (%) | Worst case (%) |
| Amoxicillin-Clavulanate | 63/63 (100%) | 63/63 (100%) | 63/63 (100%) | 63/63 (100%) |
| Ampicillin | 45/45 (100%) | 45/45 (100%) | 45/45 (100%) | 45/45 (100%) |
| Ampicillin-Sulbactam | 72/72 (100%) | 72/72 (100%) | 72/72 (100%) | 72/72 (100%) |
| Aztreonam | 71/74 (95.9%) | 68/74 (91.9%) | 71/74 (95.9%) | 68/74 (91.9%) |
| Cefazolin | 61/63 (96.8%) | 61/63 (96.8%) | 61/63 (96.8%) | 61/63 (96.8%) |
| Cefepime | 45/47 (95.7%) | 45/47 (95.7%) | 45/47 (95.7%) | 45/47 (95.7%) |
| Cefoxitin | 54/54 (100%) | 54/54 (100%) | 54/54 (100%) | 54/54 (100%) |
| Ceftazidime | 92/93 (98.9%) | 91/93 (97.8%) | 92/93 (98.9%) | 91/93 (97.8%) |
| Ceftazidime-Avibactam | 47/47 (100%) | 43/47 (91.5%) | 47/47 (100%) | 43/47 (91.5%) |
| Eravacycline | 103/103 (100%) | 99/103 (96.1%) | 103/103 (100%) | 99/103 (96.1%) |
| Gentamicin | 116/121 (95.9%) | 116/121 (95.9%) | 116/121 (95.9%) | 116/121 (95.9%) |
| Imipenem-Relebactam | 72/76 (94.7%) | 72/76 (94.7%) | 72/76 (94.7%) | 72/76 (94.7%) |
| Levofloxacin | 179/181 (98.9%) | 174/181 (96.1%) | 179/181 (98.9%) | 174/181 (96.1%) |
| Meropenem | 57/58 (98.3%) | 56/58 (96.6%) | 57/58 (98.3%) | 56/58 (96.6%) |
| Meropenem-Vaborbactam | 45/47 (95.7%) | 43/47 (91.5%) | 45/47 (95.7%) | 43/47 (91.5%) |
| Piperacillin-Tazobactam | 54/56 (96.4%) | 54/56 (96.4%) | 54/56 (96.4%) | 54/56 (96.4%) |
| Trimethoprim-Sulfamethoxazole | 62/65 (95.4%) | 61/65 (93.8%) | 62/65 (95.4%) | 61/65 (93.8%) |
Clinical Studies
The following table gives the antimicrobial-organism combinations tested and includes the reporting range and breakpoints of each combination.
| Antimicrobial | Abbreviation | Targeted Organism | Reporting Range | Breakpoints | Antimicrobial | Organism Group | Total
Tested | # in EA | % EA | # in CA | % CA | # R | # VMJ | # MAJ | # MIN |
|-----------------------------------|------------------------|----------------------------------------------------------------|------------------------|----------------------------------------------------------------------------------|-----------------------------|---------------------------------|-----------------|---------|------|---------|------|-----|-------|-------|-------|
| Amikacin | AMK | Pseudomonas
aeruginosa | ≤0.12 to ≥256
µg/mL | ≤16 / 32 / ≥64 | Amikacin | Pseudomonas aeruginosa | 165 | 150 | 90.9 | 162 | 98.2 | 7 | 0 | 0 | 3 |
| Amoxicillin-
Clavulanate | AMC | Enterobacterales | ≤0.5 to ≥128
µg/mL | ≤8 / 16 / ≥32 | Amoxicillin-
Clavulanate | Enterobacterales | 457 | 437 | 95.6 | 423 | 92.6 | 110 | 1 | 2 | 31 |
| Ampicillin | AMP | Enterobacterales | ≤0.25 to ≥128
µg/mL | ≤8 / 16 / ≥32 | Ampicillin | Enterobacterales | 254 | 241 | 94.9 | 251 | 98.8 | 118 | 1 | 1 | 1 |
| Ampicillin-
Sulbactam | SAM | Acinetobacter
baumannii complex
Enterobacterales | ≤0.5 to ≥128
µg/mL | ≤8 / 16 / ≥32 | Ampicillin-
Sulbactam | Acinetobacter baumannii complex | 123 | 113 | 91.9 | 114 | 92.7 | 52 | 1 | 2 | 6 |
| Aztreonam | ATM | Enterobacterales | ≤0.03 to ≥128
µg/mL | ≤4 / 8 / ≥16 | Aztreonam | Enterobacterales | 183 | 179 | 97.8 | 178 | 97.3 | 46 | 0 | 0 | 5 |
| Cefazolin | CFZ | Enterobacterales | ≤0.12 to ≥128
µg/mL | ≤1 / 2 / ≥4 | Cefazolin | Enterobacterales | 358 | 339 | 94.7 | 287 | 80.2 | 215 | 1 | 0 | 70 |
| Cefepime | FEP | Enterobacterales | ≤0.25 to ≥128
µg/mL | ≤2 / 4-8 / ≥16 | Cefepime | Enterobacterales | 882 | 833 | 94.4 | 845 | 95.8 | 127 | 2 | 10 | 25 |
| Cefoxitin | FOX | Enterobacterales | ≤1 to ≥128 µg/mL | ≤4 / 8 / ≥16 | Cefoxitin | Enterobacterales | 583 | 538 | 92.3 | 461 | 79.1 | 103 | 3 | 8 | 111 |
| Ceftazidime | CAZ | Enterobacterales | ≤0.25 to ≥64
µg/mL | ≤4 / 8 / ≥16 | Ceftazidime | Enterobacterales | 787 | 752 | 95.6 | 759 | 96.4 | 208 | 1 | 1 | 26 |
| Antimicrobial | Abbreviation | Targeted Organism | Reporting Range | Breakpoints | Ceftazidime-
Avibactam | Enterobacterales | 815 | 793 | 97.3 | 810 | 99.4 | 32 | 0 | 5 | 0 |
| Ceftazidime-
Avibactam | CZA | Enterobacterales
Pseudomonas
aeruginosa | ≤0.12 to ≥64
μg/mL | ≤8 / ≥16 | Ceftriaxone | Pseudomonas aeruginosa | 163 | 151 | 92.6 | 158 | 96.9 | 10 | 0 | 2 | 0 |
| Ceftriaxone | CRO | Enterobacterales | ≤0.25 to ≥32
μg/mL | ≤1 / 2 / ≥4 | Ceftriaxone | Enterobacterales | 668 | 650 | 97.3 | 657 | 98.4 | 188 | 1 | 4 | 3 |
| Ciprofloxacin | CIP | Enterobacterales
Pseudomonas
aeruginosa | ≤0.03 to ≥16
μg/mL | Enterobacterales:
≤0.25 / 0.5 / ≥1
P. aeruginosa :
≤0.5 / 1 / ≥2 | Ciprofloxacin | Enterobacterales | 818 | 791 | 96.7 | 787 | 96.2 | 177 | 2 | 3 | 26 |
| Eravacycline | ERV | Enterobacterales | ≤0.016 to ≥4
μg/mL | ≤0.5 / - | | Pseudomonas aeruginosa | 169 | 162 | 95.9 | 160 | 94.7 | 33 | 0 | 4 | 5 |
| Ertapenem | ETP | Enterobacterales | ≤0.03 to ≥16
μg/mL | ≤0.5 / 1 / ≥2 | Eravacycline | Enterobacterales | 487 | 478 | 98.2 | 480 | 98.6 | 54 | 2 | 1 | 0 |
| Gentamicin | GEN | Enterobacterales | ≤0.06 to ≥64
μg/mL | ≤4 / 8 / ≥16 | Ertapenem | Enterobacterales | 882 | 849 | 96.3 | 868 | 98.4 | 101 | 0 | 8 | 6 |
| Imipenem-
Relebactam | IMR | Enterobacterales
Pseudomonas
aeruginosa | ≤0.03 to ≥128
μg/mL | Enterobacterales:
≤1 / 2 / ≥4
P. aeruginosa :
≤2 / 4 / ≥8 | Gentamicin | Enterobacterales | 741 | 713 | 96.2 | 733 | 98.9 | 113 | 1 | 1 | 6 |
| Levofloxacin | LVX | Enterobacterales | ≤0.06 to ≥32
μg/mL | ≤0.5 / 1 / ≥2 | | Pseudomonas aeruginosa | 218 | 211 | 96.8 | 212 | 97.2 | 15 | 0 | 0 | 6 |
| Meropenem | MEM | Enterobacterales
Pseudomonas
aeruginosa | ≤0.12 to ≥64
μg/mL | Enterobacterales:
≤1 / 2 / ≥4
P. aeruginosa :
≤2 / 4 / ≥8 | Imipenem-
Relebactam | Enterobacterales | 471 | 440 | 93.4 | 459 | 97.5 | 33 | 0 | 3 | 9 |
| Meropenem-
Vaborbactam | MEV | Enterobacterales | ≤0.06 to ≥64
μg/mL | ≤4 / 8 / ≥16 | | Pseudomonas aeruginosa | 165 | 159 | 96.4 | 162 | 98.2 | 6 | 0 | 0 | 3 |
| Minocycline | MIN | Enterobacterales | ≤0.25 to ≥64
μg/mL | ≤4 / 8 / ≥16 | Levofloxacin | Enterobacterales | 784 | 753 | 96 | 744 | 94.9 | 161 | 1 | 6 | 33 |
| Piperacillin-
Tazobactam | TZP | Enterobacterales | ≤0.25 to ≥512
μg/mL | ≤16 / 32-64 / ≥128 | Meropenem | Enterobacterales | 833 | 801 | 96.2 | 816 | 98 | 83 | 1 | 12 | 4 |
| Tobramycin | TOB | Pseudomonas
aeruginosa | ≤0.12 to ≥128
μg/mL | ≤4 / 8 / ≥16 | | Pseudomonas aeruginosa | 175 | 163 | 93.1 | 168 | 96 | 38 | 0 | 0 | 7 |
| Trimethoprim-
Sulfamethoxazole | SXT | Enterobacterales | ≤0.12 to ≥32
μg/mL | ≤2 / ≥4 | Meropenem-
Vaborbactam | Enterobacterales | 760 | 727 | 95.7 | 752 | 98.9 | 41 | 1 | 1 | 6 |
| Minocycline | Enterobacterales | 391 | 353 | 90.3 | 372 | 95.1 | 37 | 1 | 3 | 16 | | | | | |
| Piperacillin-
Tazobactam | Enterobacterales | 699 | 644 | 92.1 | 680 | 97.3 | 108 | 2 | 3 | 13 | | | | | |
| Tobramycin | Pseudomonas aeruginosa | 166 | 155 | 93.4 | 162 | 97.6 | 14 | 0 | 1 | 3 | | | | | |
| Trimethoprim-
Sulfamethoxazole | Enterobacterales | 449 | 435 | 96.9 | 442 | 98.4 | 142 | 4 | 1 | 0 | | | | | |
12
Clinical performance testing on the Selux AST System was performed at three test sites. Contemporary and frozen clinical isolates from diverse geographic locations across the US were evaluated for performance as were banked challenge isolates, which were selected for their resistance profiles. A total of 1401 clinical (426 contemporary and 975 stock) and 222 challenge isolates from 12 Enterobacterales species, Acinetobacter baumannii complex, and Pseudomonas aeruginosa were tested to evaluate the Selux AST System performance for 24 antimicrobials. Depending on the spectrum of activity, breakpoints, and the claimed organisms (species/group)
13
for each antimicrobial on the panel, the number of datapoints for the various antimicrobialorganisms tested varied and ranged from 165 (e.g. P. aeruginosa/Imipenem-Relebactam) to 977 (e.g. Enterobacterales/Ertapenem).
Selux AST System performance was determined by comparing Selux AST System results with triplicate broth microdilution results performed at an independent reference laboratory. The Selux AST System meets performance criteria for each indication and is given in the following table, where performance is summarized by reporting group. Additionally, QC testing was performed every day testing was performed at each site and met the 95% performance criteria for all antimicrobials.
Conclusion
Based on our studies and testing, the Selux AST System was determined to be substantially equivalent to the predicate device (K190905).